INVH Shares Jump on FDA-Style Patent Approval for Modified INVOcell Device

INVH shares surged over 12% on February 11, 2026, following the issuance of a patent for a modified INVOcell device, a key innovation in the fertility treatment space. The patent, granted by the United States Patent and Trademark Office, reinforces the company’s competitive moat and expands its intellectual property protection for its proprietary technology. The approval follows positive internal trial results and strengthens INVH’s position in the high-growth fertility sector. The company plans to leverage the patent to expand its product line and defend against potential generics. The stock closed at $14.25 on the NASDAQ, up $1.70 from the prior day’s close.